Floatz logo

Ruxolitinib

Steroid-Refractory Acute Graft Versus Host Disease

XenikosSmall moleculePhase 3Active
B
59/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
44/ 100
Competitive Position
95/ 100

Competitive context

3 Active assets in the Steroid-Refractory Acute Graft Versus Host Disease cohort.

Asset / SponsorPhaseRating
METHOTREXATE
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
Basiliximab
Zhongming Zhang
Phase 4BB
TACROLIMUS
Oncoimmune, Inc., a subsidiary of Merck & Co., Inc. (Rahway, New Jersey USA)
Phase 4BB
Lactobacillus Plantarum Strain 299V
Children's Oncology Group
Phase 3B
Cyclophosphamide
Stanford University
Phase 2B

View all 14 →

Same molecule, other indications

Ruxolitinib is also rated in:

primary myelofibrosisDormant
BBB
Indicative ·
73 / 100
View asset →
disease related to hematopoietic stem cell transplantDormant
BB
Indicative ·
70 / 100
View asset →
graft versus host diseaseDormant
BB
Indicative ·
70 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →